Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DBPR108 DDI with Metformin, Glibenclamide, Valsartan, Simvastatin in Healthy Subjects
NCT04859452Phase 1Completed
- Sponsor
- CSPC ZhongQi Pharmaceutical Technology
- Start
- May 2021
- Primary completion
- Jul 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of prusogliptin in type 2 diabetes mellitus (T2DM) (4 arms), sponsored by CSPC ZhongQi Pharmaceutical Technology. Primary endpoint: Pharmacokinetic parameters of Metformin, Glibenclamide, Valsartan, Simvastatin, Simvastatin acid and DBPR108. Started May 2021; status: completed.
02
Drugs
prusogliptin
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT04859452.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04859452.